Elsevier

Clinical Therapeutics

Volume 28, Issue 4, April 2006, Pages 475-490
Clinical Therapeutics

Once-monthly Ibandronate for postmenopausal Osteoporosis: Review of a new dosing regimen

https://doi.org/10.1016/j.clinthera.2006.04.006Get rights and content

Abstract

Background:

Ibandronate, a nitrogen-containing bisphosphonate, was approved by the US Food and Drug Administration (FDA) in May 2003 as a daily oral regimen for the treatment and prevention of post-menopausal osteoporosis. In March 2005, the FDA approved once-monthly dosing with ibandronate for the same indications.

Objective:

The purpose of this article was to review the efficacy and tolerability of ibandronate 150 mg once monthly in the treatment and prevention of post-menopausal osteoporosis.

Methods:

A search of MEDLINE (1966-September 2005) and International Pharmaceutical Abstracts (1971-September 2005) for articles relating to the efficacy and tolerability of once-monthly ibandronate in the treatment of postmenopausal osteoporosis was conducted using the terms ibandronate and ibandronic acid. Additional searches were conducted to identify publications relevant to compliance and pharmacoeconomic considerations using the terms bispbospbonate, compliance, cost, and pharmacoeconomics. The reference lists of identified articles and presentations from recent scientific meetings also were reviewed. Selected safety information from the manufacturer was incorporated.

Results:

Ibandronate 2.5 mg/d and intermittent ibandronate (20 mg QOD for 12 doses every 3 months) have been shown to effectively reduce the incidence of vertebral fractures; after 3 years of therapy in a placebo-controlled clinical trial, the relative risk reductions for new vertebral fractures with daily and intermittent ibandronate were 62% and 50%, respectively (both, P < 0.001 vs placebo). Once-monthly ibandronate has been evaluated in 2 clinical trials: a Phase I dose-ranging trial in 144 healthy postmenopausal women and a Phase III noninferiority trial in 1609 women with postmenopausal osteoporosis who were randomized to receive ibandronate 2.5 mg/d or 1 of 3 monthly ibandronate regimens: 50/50 mg (50 mg given on 2 consecutive days) once monthly; 100 mg once monthly; and 150 mg once monthly. The primary end point of the Phase III trial was the change from baseline in lumbar spine bone mineral density (BMD). After 1 year of therapy, patients who received ibandronate 150 mg once monthly had a significantly greater increase from baseline in lumbar spine BMD compared with those who received ibandronate 2.5 mg/d (4.9% vs 3.9%, respectively; P = 0.002). The overall adverse-event profile was similar between the daily and monthly regimens. Drug-related adverse events were reported in 32.4% of patients receiving ibandronate 2.5 mg/d and 36.9% of patients receiving ibandronate 150 mg monthly. Upper gastrointestinal adverse events occurred in a respective 22.8% and 22.5% of the 2 groups. After 1 year of therapy, patients receiving ibandronate 150 mg monthly reported more flulike symptoms (8.3%) compared with those receiving ibandronate 2.5 mg/d (2.8%). In a crossover study comparing preference for and convenience of monthly ibandronate and weekly alendronate in 342 ambulatory women with postmenopausal osteoporosis, significantly more patients preferred the monthly ibandronate regimen to the weekly alendronate regimen (71.4% vs 28.5%, respectively; P < 0.001).

Conclusion:

Once-monthly ibandronate is an effective and well-tolerated treatment option for postmenopausal osteoporosis.

References (82)

  • De CockE. et al.

    Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom

    Clin Ther.

    (2005)
  • FelsenbergD. et al.

    The bone quality framework: Determinants of bone strength and their interrelationships, and implications for osteoporosis management

    Clin Ther.

    (2005)
  • GuyattG.H. et al.

    Summary of meta-analyses of therapies for postmenopausal os teoporosis and the relationship between bone density and fractures

    Endocrinol Metab Clin North Am.

    (2002)
  • EpsteinS.

    The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy

  • TripathyD. et al.

    Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial

    Ann Oncol.

    (2004)
  • BodyJ.J. et al.

    Oral ibandronate improves bone pain and preserves quality of life in pa tients with skeletal metastases due to breast cancer

    Pain

    (2004)
  • BodyJ.J. et al.

    Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

    Ann Oncol.

    (2003)
  • DielI.J. et al.

    Improved quality of life after long term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer

    Eur J Cancer.

    (2004)
  • TripathyD. et al.

    Review of ibandronate in the treatment of metastatic bone disease: Experience from phase III trials

    Clin Ther.

    (2004)
  • Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

    World Health Organ Tech Rep Ser.

    (1994)
  • Diet, nutrition and the prevention of chronic diseases

    World Health Organ Tech Rep Ser.

    (2003)
  • National Osteoporosis Foundation. Advocacy News & Updates. America's Bone Health

    The State of Osteoporosis and Low Bone Mass

  • Bone Health and Osteoporosis: A Report of the Surgeon General

    (October 14, 2004)
  • LeibsonC.L. et al.

    Mortality, disability, and nursing home use for persons with and without hip fracture: A population-based study

    J Am Geriatr Soc.

    (2002)
  • RichmondJ. et al.

    Mortality risk after hip fracture. 2003

    J Orthop Trauma.

    (2003)
  • GreenblattD.

    Treatment of postmenopausal osteoporosis

    Pharmacotherapy

    (2005)
  • PandeI. et al.

    Oral antiresorptive therapy

    Curr Rheumatol Rep.

    (2005)
  • KleerekoperM.

    Prevention of postmenopausal bone loss and treatment of osteoporosis

    Semin Reprod Med.

    (2005)
  • O'ConnellM.B. et al.

    Osteoporosis and osteomalacia

  • DelmasP.D.

    The use of bisphosphonates in the treatment of osteoporosis

    Curr Opin Rheumatol.

    (2005)
  • DooleyM. et al.

    Ibandronate

    Drugs

    (1999)
  • BaussF. et al.

    Ibandronate in osteoporosis: Preclinical data and rationale for intermittent dosing

    Osteoporos Int.

    (2004)
  • MuhlbauerR.C. et al.

    BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

    J Bone Miner Res.

    (1991)
  • BarrettJ. et al.

    Ibandronate: A clinical pharmacological and pharmacokinetic up date

    J Clin Pharmacol.

    (2004)
  • BaussF. et al.

    Ibandronate: Serum kinetics, tissue distribution and bind ing to bone following intravenous bolus injection

    Calcif Tissue Int.

    (2002)
  • Monier-FaugereM.C. et al.

    Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: Effects on bone morphometry and mineral properties

    J Bone Miner Res.

    (1999)
  • ChestnutC.H. et al.

    Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis

    J Bone Miner Res.

    (2004)
  • ReginsterJ.Y. et al.

    Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: Results from the monthly oral pilot study

    J Clin Endocrinol Metab.

    (2005)
  • MillerP.D. et al.

    Monthly oral ibandronate therapy in postmenopausal osteo porosis: 1-Year results from the MOBI LE study

    J Bone Miner Res.

    (2005)
  • Cited by (0)

    View full text